Savara Earnings Reports

Savara posted a larger net loss in Q3 2025 compared to the previous year due to increased R&D and G&A expenses, as the company progresses its MOLBREEVI development and prepares for commercialization.

Savara Inc. experienced a larger net loss in the first quarter of 2025 compared to the same period last year, driven by significant increases in research and development and general and administrative expenses. The company continues to focus on the development of its product candidate, MOLBREEVI, and maintains a strong cash position to fund its planned activities.

In Q4 2024, Savara posted a net loss of $29.04 million or $(0.13) per share, primarily due to increased investment in research and development and commercial preparation for MOLBREEVI. The company ended the quarter with strong liquidity, holding $196.33 million in cash and short-term investments.

Savara reported a net loss attributable to common stockholders of $9.4 million, or $(0.16) per share, for the three months ended June 30, 2020. The company had cash, cash equivalents, and short-term investments of approximately $100 million as of June 30, 2020.

Savara reported a net loss attributable to common stockholders of $15.4 million, or $(0.27) per share, for the three months ended March 31, 2020. As of March 31, 2020, Savara had cash, cash equivalents, and short-term investments of approximately $105 million.

Savara reported positive results from the IMPALA open-label follow-up, is planning an additional Phase 3 study of Molgradex for aPAP, and announced top-line microbiology data from OPTIMA. The company's net loss for the fourth quarter of 2019 was $31.7 million, or $(0.72) per share.